Parkinson’s disease treatment is used to treat the symptoms of Parkinson’s disease, generally, medication is the first line treatment for this disease.
The global Parkinson’s disease treatment market is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1%. Rising geriatric population and government funding for research on Parkinson’s disease are the driving factors for this market.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247
The Parkinson’s disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region
"Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022"
Currently, a wide range of treatments is available for alleviating the symptoms of Parkinson’s disease. Medication is the first line therapy for treating the disease; however, they are not effective in all stages of the disease.
In the severe stages, medications do not show pharmacological action in relieving disease symptoms. Neurologists perform thalamotomy, pallidotomy, or implant deep brain stimulation (DBS) devices in order to ease symptoms.
Target Audience for this Report:
- Parkinson’s disease treatment product manufacturers
- Parkinson’s disease treatment dealers and suppliers
- Human identification service providers
- Parkinson’s disease associations
- Academic institutions
- Venture capitalists
- Consulting firms
To Know More @ https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html
No comments:
Post a Comment